MX2009004884A - Derivados 8-piperidinil-2-piridinil-pirimido [1,2-a] pirimidin-6-ona y 8-piperidinil-2-pirimidinil-pirimido [1,2-a] pirimidin-6-ona sustuidos. - Google Patents
Derivados 8-piperidinil-2-piridinil-pirimido [1,2-a] pirimidin-6-ona y 8-piperidinil-2-pirimidinil-pirimido [1,2-a] pirimidin-6-ona sustuidos.Info
- Publication number
- MX2009004884A MX2009004884A MX2009004884A MX2009004884A MX2009004884A MX 2009004884 A MX2009004884 A MX 2009004884A MX 2009004884 A MX2009004884 A MX 2009004884A MX 2009004884 A MX2009004884 A MX 2009004884A MX 2009004884 A MX2009004884 A MX 2009004884A
- Authority
- MX
- Mexico
- Prior art keywords
- optionally substituted
- ring
- pyrimido
- pyrimidin
- piperidinyl
- Prior art date
Links
- SRGMSBSWSBBEDF-UHFFFAOYSA-N 2-piperidin-1-yl-8-pyridin-2-ylpyrimido[1,2-a]pyrimidin-4-one Chemical class C1=CN2C(=O)C=C(N3CCCCC3)N=C2N=C1C1=CC=CC=N1 SRGMSBSWSBBEDF-UHFFFAOYSA-N 0.000 title 1
- FLQSRVBGRGVAEU-UHFFFAOYSA-N 2-piperidin-1-yl-8-pyrimidin-2-ylpyrimido[1,2-a]pyrimidin-4-one Chemical class C1=CN2C(=O)C=C(N3CCCCC3)N=C2N=C1C1=NC=CC=N1 FLQSRVBGRGVAEU-UHFFFAOYSA-N 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 150000008318 pyrimidones Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
Abstract
La invención se refiere a un derivado de pirimidona representado por la fórmula (I) o una sal de éste, en la que: X representa dos átomos de hidrógeno, un átomo de azufre, un átomo de oxígeno o un grupo alquilo C1-2 y un átomo de hidrógeno; Y representa un enlace, un grupo carbonilo o un grupo metileno sustituido opcionalmente; R1 representa un anillo de 2, 3 ó 4-piridina o un anillo de 2, 4 ó 5-pirimidina, estando el anillo sustituido opcionalmente; R2 representa un anillo de benceno o un anillo de naftaleno; estando los anillos sustituidos opcionalmente; R3 representa un átomo de hidrógeno, un grupo alquilo C1-6 o un átomo de halógeno; R4 representa un átomo de hidrógeno, un grupo alcoxi carbonilo C1-6 o un grupo alquilo C1-6 sustituido opcionalmente; n representa 0 a 3; p representa 2; q representa 0; o representa 0, 1 ó 2 y m representa respectivamente 4, 3 ó 2, siendo o+m igual a 4. La invención también se refiere a un medicamento que contiene dicho derivado o una sal de él como un ingrediente activo que se usa para tratamiento preventivo y/o terapéutico de una enfermedad neurodegenerativa causada por la actividad anormal de GSK3ß, tal como la enfermedad de Alzheimer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06291725A EP1921080B1 (en) | 2006-11-07 | 2006-11-07 | Subsitituted 8-piperidinyl-2-pyridinyl-pyrimido(1,2-a)pyrimidin-6-one and 8-piperidinyl-2-pyrimidinyl-pyrimido(1,2-a)pyrimidin-6-one derivatives |
| PCT/IB2007/004272 WO2008056266A2 (en) | 2006-11-07 | 2007-11-06 | Substituted 8-piperidinyl-2-pyridinyl-pyrimido [1,2-a]pyrimidin-6-one and 8-piperidinyl-2-pyrimidinyl-pyrimido[1,2-a]pyrimidin-6-one derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009004884A true MX2009004884A (es) | 2009-05-21 |
Family
ID=38331403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009004884A MX2009004884A (es) | 2006-11-07 | 2007-11-06 | Derivados 8-piperidinil-2-piridinil-pirimido [1,2-a] pirimidin-6-ona y 8-piperidinil-2-pirimidinil-pirimido [1,2-a] pirimidin-6-ona sustuidos. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20090281121A1 (es) |
| EP (2) | EP1921080B1 (es) |
| JP (1) | JP2010509203A (es) |
| KR (1) | KR20090091123A (es) |
| CN (1) | CN101535314A (es) |
| AR (1) | AR063577A1 (es) |
| AU (1) | AU2007318927A1 (es) |
| BR (1) | BRPI0718519A2 (es) |
| CA (1) | CA2668682A1 (es) |
| EA (1) | EA016251B1 (es) |
| IL (1) | IL198239A0 (es) |
| MX (1) | MX2009004884A (es) |
| NZ (1) | NZ576773A (es) |
| TW (1) | TW200835495A (es) |
| WO (1) | WO2008056266A2 (es) |
| ZA (1) | ZA200902630B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| FR2992316A1 (fr) * | 2012-06-22 | 2013-12-27 | Sanofi Sa | Derives de pyrimidinones, leur preparation et leur application en therapeutique |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2530068A1 (en) * | 2003-06-30 | 2005-01-06 | Merck Frosst Canada Ltd. | Cyanoalklamino derivatives useful as cathepsin cysteine protease inhibitors |
| EP1557417B1 (en) * | 2003-12-19 | 2007-03-07 | Sanofi-Aventis | Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a] pyrimidin-6-one derivatives |
-
2006
- 2006-11-07 EP EP06291725A patent/EP1921080B1/en not_active Expired - Fee Related
-
2007
- 2007-11-06 WO PCT/IB2007/004272 patent/WO2008056266A2/en not_active Ceased
- 2007-11-06 AR ARP070104932A patent/AR063577A1/es unknown
- 2007-11-06 AU AU2007318927A patent/AU2007318927A1/en not_active Abandoned
- 2007-11-06 EP EP07859310A patent/EP2081938A2/en not_active Withdrawn
- 2007-11-06 CA CA002668682A patent/CA2668682A1/en not_active Abandoned
- 2007-11-06 JP JP2009535149A patent/JP2010509203A/ja not_active Withdrawn
- 2007-11-06 KR KR1020097009377A patent/KR20090091123A/ko not_active Withdrawn
- 2007-11-06 BR BRPI0718519-7A patent/BRPI0718519A2/pt not_active IP Right Cessation
- 2007-11-06 ZA ZA200902630A patent/ZA200902630B/xx unknown
- 2007-11-06 MX MX2009004884A patent/MX2009004884A/es active IP Right Grant
- 2007-11-06 EA EA200970455A patent/EA016251B1/ru not_active IP Right Cessation
- 2007-11-06 TW TW096141872A patent/TW200835495A/zh unknown
- 2007-11-06 CN CNA200780041338XA patent/CN101535314A/zh active Pending
- 2007-11-06 NZ NZ576773A patent/NZ576773A/en not_active IP Right Cessation
-
2009
- 2009-04-20 IL IL198239A patent/IL198239A0/en unknown
- 2009-05-01 US US12/434,053 patent/US20090281121A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0718519A2 (pt) | 2014-04-15 |
| ZA200902630B (en) | 2010-06-30 |
| IL198239A0 (en) | 2009-12-24 |
| WO2008056266A3 (en) | 2008-07-10 |
| TW200835495A (en) | 2008-09-01 |
| KR20090091123A (ko) | 2009-08-26 |
| WO2008056266A8 (en) | 2009-06-18 |
| EP2081938A2 (en) | 2009-07-29 |
| EP1921080A1 (en) | 2008-05-14 |
| CN101535314A (zh) | 2009-09-16 |
| EA016251B1 (ru) | 2012-03-30 |
| EA200970455A1 (ru) | 2009-12-30 |
| AU2007318927A1 (en) | 2008-05-15 |
| CA2668682A1 (en) | 2008-05-15 |
| AR063577A1 (es) | 2009-02-04 |
| WO2008056266A2 (en) | 2008-05-15 |
| EP1921080B1 (en) | 2009-08-05 |
| JP2010509203A (ja) | 2010-03-25 |
| US20090281121A1 (en) | 2009-11-12 |
| NZ576773A (en) | 2011-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009004884A (es) | Derivados 8-piperidinil-2-piridinil-pirimido [1,2-a] pirimidin-6-ona y 8-piperidinil-2-pirimidinil-pirimido [1,2-a] pirimidin-6-ona sustuidos. | |
| TW200510418A (en) | Substituted 8'-pyridinyl-dihydrospiro-[cycloalkyl]-pyrimido [1, 2-a] pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro-[cycloalkyl]-pyrimido [1, 2-a] pyrimidin-6-one derivatives | |
| TW200504070A (en) | 8-substituted-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives | |
| TW200505922A (en) | Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives | |
| EA200601192A1 (ru) | ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ 8'-ПИРИ(МИ)ДИНИЛДИГИДРОСПИРО[ЦИКЛОАЛКИЛАМИН]ПИРИМИДО[1,2-a]ПИРИМИДИН-6-ОНА | |
| WO2007057790A3 (en) | Substituted bicyclic pyrimidone derivatives | |
| EA201170095A1 (ru) | Производные (4-пиридин-4-ил)-1h-(1,3,5) триазин-2-она в качестве ингибирования gsk3-бета для лечения нейродегенеративных заболеваний | |
| TN2014000042A1 (en) | Cyclopropaneamine compound | |
| WO2005092895A3 (en) | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists | |
| HUP0303164A2 (hu) | Kinazolinok mint MMP-13 gátlók, eljárás az előállításukra, intermedierjeik és a vegyületeket tartalmazó gyógyszerkészítmények | |
| MX2009006024A (es) | Derivados de heteroaril piridopirimidona sustituidos. | |
| MX2009006947A (es) | Derivados de pirimidona 6-heterociclica 2-sustituida. | |
| MX2010008363A (es) | Derivados de arilamida diazepinopirimidona sustituidos para el tratamiento de enfermedades neurodegenerativas causadas por la actividad anormal de gsk3-beta. | |
| MX2010005753A (es) | Derivados de isoxazolo-pirazina. | |
| EP1396493A4 (en) | HETEROCYCLIC COMPOUNDS | |
| EA201270359A1 (ru) | Терапевтическое средство от расстройств настроения | |
| PH12020550168A1 (en) | Griseofulvin compound and pharmaceutical use thereof | |
| SG161217A1 (en) | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents | |
| GEP20115240B (en) | Indole derivatives, process for their preparation and pharmaceutical compositions containing them | |
| EA200870492A1 (ru) | N-оксиды производных пиридилметилпиперазина и - пиперидина | |
| WO2009016812A1 (ja) | ２－フェニルキノリン－４－カルボン酸誘導体を有効成分とする貧血の予防及び／又は治療剤 | |
| TH69758A (th) | อนุพันธ์สับสติติวท์ 8-เปอร์ฟลูออโรอัลคิล-6,7,8,9-เตตราไฮโดรไพริมิโด[1,2-a]ไพริมิดิน-4-โอน | |
| TH74460A (th) | อนุพันธ์ของ 8'-พิริ(มิ)ดินิล-ไดไฮโดรสไปโร-[ไซโคลอัลคิลามีน]-พิริมิโด[1,2-a]พิริมิดิน-6-โอน ที่ถูกแทนที่ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| HH | Correction or change in general |